Desvenlafaxine Succinate Tablet, Film Coated, Extended Release
Product Images NDC 68180-593

14 FDA label images from Lupin Pharmaceuticals, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine Succinate (NDC 68180-593). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Lupin Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (748a4941 405f 436f 933b 0bec4b119e3c 01)

Image (748a4941 405f 436f 933b 0bec4b119e3c 01)
Chemical structure of Desvenlafaxine Succinate, showing its molecular arrangement including a cyclohexanol group, a phenol ring with a methylated amine side chain, and succinic acid with a water molecule of hydration.*
FDA Label Image

Image (748a4941 405f 436f 933b 0bec4b119e3c 02)

Image (748a4941 405f 436f 933b 0bec4b119e3c 02)
A chart titled 'Impact of Intrinsic Factors (Renal, Hepatic Impairment and Population Description) on Desvenlafaxine Pharmacokinetics' displaying geometric mean ratios with 90% confidence intervals for Cmax and AUC parameters. It compares mild, moderate, severe renal and hepatic impairment, and population groups based on gender and age, showing changes relative to reference values for Desvenlafaxine pharmacokinetics.*
FDA Label Image

Image (748a4941 405f 436f 933b 0bec4b119e3c 03)

Image (748a4941 405f 436f 933b 0bec4b119e3c 03)
A pharmacokinetic chart showing the effect of CYP3A4 inhibitor ketoconazole on desvenlafaxine. It presents geometric mean ratios with 90% confidence intervals for Cmax and AUC, indicating changes relative to reference values.*
FDA Label Image

Image (748a4941 405f 436f 933b 0bec4b119e3c 04)

Image (748a4941 405f 436f 933b 0bec4b119e3c 04)
A forest plot chart titled "Effects of Desvenlafaxine on Pharmacokinetics of Other Drugs." It displays geometrical mean ratios with 90% confidence intervals for various interacting drugs (Desipramine, Midazolam, Tamoxifen, Aripiprazole) at different Desvenlafaxine dosages (50 mg, 100 mg, 400 mg). The plot compares Cmax and AUC values, showing changes relative to reference values across CYP2D6 and CYP3A4 substrates.*
FDA Label Image

Image (748a4941 405f 436f 933b 0bec4b119e3c 05)

Image (748a4941 405f 436f 933b 0bec4b119e3c 05)
A line graph titled 'Estimated Proportion of Relapses vs. Number of Days since Randomization (Study 5)', showing relapse rates over time in days up to 200. It compares two groups: Desvenlafaxine extended-release tablets 50 mg and placebo. The y-axis represents the estimated proportion of patients with relapse (%), showing lower relapse rates for Desvenlafaxine 50 mg compared to placebo over the study period.*
FDA Label Image

Image (748a4941 405f 436f 933b 0bec4b119e3c 06)

Image (748a4941 405f 436f 933b 0bec4b119e3c 06)
A Kaplan-Meier curve chart showing the estimated proportion of patients with relapse (%) over time in days from randomization for Desvenlafaxine extended-release tablets versus placebo. The chart compares relapse rates between the two treatments, with a solid line for Desvenlafaxine and a dashed line for placebo.*
FDA Label Image

Image (8c54cb6e C89e 4613 81f3 Cd24467fd163 1166 1)

Image (8c54cb6e C89e 4613 81f3 Cd24467fd163 1166 1)
Desvenlafaxine Succinate extended-release film-coated tablets in three white circular tablets, each marked with an imprint. The tablets likely represent the available strengths 25 mg, 50 mg, and 100 mg, but specific imprints or strengths are not visible. Labeler is Lupin Pharmaceuticals, Inc.*
FDA Label Image

Image (8c54cb6e C89e 4613 81f3 Cd24467fd163 1198 1)

Image (8c54cb6e C89e 4613 81f3 Cd24467fd163 1198 1)
An illustration showing the process of oral administration, represented by an arrangement of capsules or tablets forming a downward arrow pointing toward a human figure, indicating ingestion and internal delivery of medication.*
FDA Label Image

25mg-30s (748a4941 405f 436f 933b 0bec4b119e3c 07)

25mg-30s (748a4941 405f 436f 933b 0bec4b119e3c 07)
Label for Desvenlafaxine Extended-Release Tablets, 25 mg strength, in a unit of use containing 30 film-coated extended-release tablets. The label includes the NDC 68180-604-06, instructions for pharmacists to dispense the Medication Guide, storage conditions, and manufacturer information: Lupin Pharmaceuticals, Inc. and Lupin Limited, India. A barcode and a QR code for the Medication Guide are also present.*
FDA Label Image

25 mg-30s Pack (748a4941 405f 436f 933b 0bec4b119e3c 08)

25 mg-30s Pack (748a4941 405f 436f 933b 0bec4b119e3c 08)
Label for Desvenlafaxine Extended-Release Tablets 25 mg, film-coated, extended-release oral tablets. The package contains 30 tablets and is manufactured by Lupin Pharmaceuticals, Inc. The label includes dosage instructions, storage conditions, a barcode, a QR code for the medication guide, and states the product is made in India by Lupin Limited.*
FDA Label Image

50mg-30s (748a4941 405f 436f 933b 0bec4b119e3c 09)

50mg-30s (748a4941 405f 436f 933b 0bec4b119e3c 09)
Desvenlafaxine Extended-Release Tablets 50 mg film-coated tablet label. The packaging indicates the product is Rx only, with a unit of use of 30 tablets. Manufactured for Lupin Pharmaceuticals, Inc. and by Lupin Limited, India. Includes dosage and storage information, pharmacisit instructions to dispense Medication Guide, NDC 68180-592-06, and a QR code linking to the Medication Guide online.*
FDA Label Image

Image (748a4941 405f 436f 933b 0bec4b119e3c 10)

Image (748a4941 405f 436f 933b 0bec4b119e3c 10)
Desvenlafaxine Extended-Release Tablets 50 mg film-coated, extended-release tablets label. The label states the product contains 76 mg of desvenlafaxine succinate monohydrate equivalent to 50 mg desvenlafaxine, manufactured by Lupin Pharmaceuticals, Inc. It is packaged as 30 tablets, Rx only, with storage instructions and a QR code linking to a medication guide. The label is marked for use in the United States and India.*
FDA Label Image

100mg-30s (748a4941 405f 436f 933b 0bec4b119e3c 12)

100mg-30s (748a4941 405f 436f 933b 0bec4b119e3c 12)
Desvenlafaxine Extended-Release Tablets 100 mg film-coated, extended-release oral tablets packaging label. The label includes the NDC 68180-593-06, instructions for pharmacists, storage information, and manufacturer details for Lupin Pharmaceuticals, Inc. and Lupin Limited. The package contains 30 tablets and features a barcode and a QR code linking to the medication guide online.*
FDA Label Image

Image (748a4941 405f 436f 933b 0bec4b119e3c 11)

Image (748a4941 405f 436f 933b 0bec4b119e3c 11)
Label for Desvenlafaxine Extended-Release Tablets 100 mg by Lupin Pharmaceuticals, Inc. The film-coated, extended-release tablets contain desvenlafaxine succinate monohydrate equivalent to 100 mg desvenlafaxine. The package contains 30 tablets and is intended for oral use, dispensed with a medication guide. Manufactured by Lupin Limited, Goa, India.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.